Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SCOTUS to weigh 'materiality proof' question in Amgen class action case

This article was originally published in Scrip

Executive Summary

The US Supreme Court on 11 June said it would hear an appeal from Amgen claiming a lower court erred when it said a group of investors could move forward with a securities fraud class-action lawsuit alleging the biotech giant downplayed the US FDA's safety concerns about Aranesp (darbepoetin alfa) and Epogen (epoetin alfa) and caused the firm's stock prices to be inflated.

Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC017721

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel